1-7 of 7
Jian Mei
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

EPCORE FL-2 Phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy (CIT) in previously untreated follicular lymphoma (FL): Trial in progress

Free
Paolo Strati, Philip Thompson, David Andorsky, Stefano Luminari, Kim Linton, Poliana Patah, Jian Mei, Neha Joshi, Neha Dixit, Elena Favaro, Emmanuel Bachy
Journal: Blood
Blood (2025) 146 (Supplement 1): 5393.
https://doi.org/10.1182/blood-2025-5393
Published: 2025
Journal Articles

primary Phase 3 results from the epcore FL-1 trial of epcoritamab with rituximab and lenalidomide (R2) versus R2 for relapsed or refractory follicular lymphoma

Free
Lorenzo Falchi, Marcel Nijland, Huiqiang Huang, Kim Linton, John Seymour, Rong Tao, Michal Kwiatek, Abel Costa, Theodoros Vassilakopoulos, Richard Greil, Ana Jiménez Ubieto, Shane Gangatharan, Ohad Benjamini, Catherine Thieblemont, Alessandra Tucci, Anna Elinder-Camburn, Arpad Illes, Jan Novak, Miguel Pavlovsky, Andrew McDonald, Dok Hyun Yoon, Yuko Mishima, Gauri Sunkersett, Jian Mei, Nabanita Mukherjee, Feng Zhu, Elena Favaro, Franck Morschhauser
Journal: Blood
Blood (2025) 146 (Supplement 1): 466.
https://doi.org/10.1182/blood-2025-466
Published: 2025
Journal Articles

Epcoritamab with rituximab + lenalidomide (R2) and epcoritamab maintenance deliver deep and durable remissions in previously untreated (1L) follicular lymphoma (FL): 3-year outcomes from epcore NHL-2 arms 6 and 7

Free
Lori Leslie, Gerardo Musuraca, Pau Abrisqueta, Joshua Brody, Jacob Christensen, Alexander Fosså, Marjolein Van Der Poel, Joost Vermaat, Fritz Offner, David Belada, Jian Mei, Isil Altintas, Malene Risum, Aidan Reilly, Liwei Wang, Lorenzo Falchi
Journal: Blood
Blood (2025) 146 (Supplement 1): 465.
https://doi.org/10.1182/blood-2025-465
Published: 2025
Journal Articles

Health-related quality of life (HRQoL) in patients with relapsed/refractory follicular lymphoma treated with epcoritamab in combination with rituximab plus lenalidomide (E+R2): Primary results of the EPCORE FL-1 trial

Free
Kim Linton, Franck Morschhauser, Marcel Nijland, Huiqiang Huang, John Seymour, Catherine Thieblemont, Abualbishr Alshreef, Jennifer Lord-Bessen, Rajesh Kamalakar, Zhijie Ding, Gauri Sunkersett, Jian Mei, Lorenzo Falchi
Journal: Blood
Blood (2025) 146 (Supplement 1): 5370.
https://doi.org/10.1182/blood-2025-5370
Published: 2025
Journal Articles

Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

Free
Firas El Chaer, James McCloskey, Lindsay A.M. Rein, Randy A. Brown, Steven D. Green, Jeffrey J. Pu, Shuichi Shirane, Kazuya Shimoda, Michiko Ichii, Junichiro Yuda, Joseph Scandura, Sujan Kabir, Jason M Foulks, Jian Mei, Huyuan Yang, Mark Wade, Carl Stapinski, Claudia Lebedinsky, Raajit K Rampal
Journal: Blood
Blood (2022) 140 (Supplement 1): 594–595.
https://doi.org/10.1182/blood-2022-159086
Published: 2022
Journal Articles

A Phase 1 Study of TP-3654, an Orally-Delivered PIM Kinase Inhibitor, in Patients with Intermediate-2 or High-Risk Primary or Secondary Myelofibrosis

Free
Claudia Lebedinsky, MD, Stephen P. Anthony, DO, Golam Mohi, PhD, Huyuan Yang, PhD, Jian Mei, PharmD, Edgar Braendle, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-134039
Published: 2020
Journal Articles

Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2

Free
Ji-yan Liu, Yu-quan Wei, Li Yang, Xia Zhao, Ling Tian, Jian-mei Hou, Ting Niu, Fen Liu, Yu Jiang, Bing Hu, Yang Wu, Jing-mei Su, Yan-yan Lou, Qiu-ming He, Yan-jun Wen, Jin-liang Yang, Bing Kan, Yong-qiu Mao, Feng Luo, Feng Peng
Journal: Blood
Blood (2003) 102 (5): 1815–1823.
https://doi.org/10.1182/blood-2002-12-3772
Published: 2003